Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals

JAMA Neurology

Volumn 73, Issue 10, 2016, Pages 1185-1191

  Mormino, Elizabeth C ^a   Papp, Kathryn V ^a   Rentz, Dorene M ^a   Schultz, Aaron P ^a   LaPoint, Molly ^a   Amariglio, Rebecca ^a   Hanseeuw, Bernard ^a   Marshall, Gad A ^a   Hedden, Trey ^a   Johnson, Keith A ^a   Sperling, Reisa A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN MAPPING; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SUSPECTED NON ALZHEIMER DISEASE PATHOPHYSIOLOGY; TAUOPATHY; CLASSIFICATION; COGNITIVE DYSFUNCTION; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TAU PROTEINS; TAUOPATHIES; THIAZOLES;

EID: 84998911409     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.2237     Document Type: Article

References (37)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580): 353-356.
3. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
4. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765-775.
5. Jack CR Jr, Knopman DS, Chételat G, et al. Suspected non-Alzheimer disease pathophysiology: concept and controversy. Nat Rev Neurol. 2016;12 (2):117-124.
6. Chételat G. Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Nat Rev Neurol. 2013;9(3):123-124.
7. Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732-1740.
8. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73(4):472-480.
9. Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70(12):1512-1519.
10. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): acommon pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766.
11. Jack CR Jr. PART and SNAP. Acta Neuropathol. 2014;128(6):773-776.
12. Jellinger KA, Alafuzoff I, Attems J, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015;129(5):757-762.
13. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
14. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5): 362-381.
15. Duyckaerts C, Braak H, Brion JP, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015; 129(5):749-756.
16. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34 (2):457-468.
17. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79 (1):110-119.
18. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78 (20):1576-1582.
19. Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71(11): 1379-1385.
20. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-2414.
22. Wechsler D. Wechsler Memory Scale-Revised. San Antonio, TX: The Psychological Corp; 1987.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
24. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355.
25. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measuresofdecline inAD and MCI. Neurobiol Aging. 2011;32(7):1207-1218.
26. Mormino EC, Betensky RA, Hedden T, et al; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOEϵ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.
27. Amariglio RE, Mormino EC, Pietras AC, et al. Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology. 2015;85(1):56-62.
28. Papp KV, Amariglio RE, Mormino EC, et al. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia. 2015;73:169-175.
29. Donohue MC, Sperling RA, Salmon DP, et al; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Cooperative Study. The preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.
30. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severityin very mild to mildADdementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510.
31. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
32. Dawe RJ, Bennett DA, Schneider JA, Arfanakis K. Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PLoS One. 2011;6(10): e26286.
33. Josephs KA, Whitwell JL, Tosakulwong N, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Ann Neurol. 2015;78(5):697-709.
34. Raz N, Gunning-Dixon F, Head D, Rodrigue KM, Williamson A, Acker JD. Aging, sexual dimorphism, and hemispheric asymmetry of the cerebral cortex: replicability of regional differences in volume. Neurobiol Aging. 2004;25(3):377-396.
35. Knopman DS, Jack CR Jr, Wiste HJ, et al. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging. 2014;35(9):2096-2106.
36. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58(5):750-757.
37. Thal DR, Beach TG, Zanette M, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology. Alzheimers Dement. 2015;11(8):975-985.